Discover how personalized medicine has changed the lives and treatment options for patients like Richard Heimler. 

  

Richard-Heimler.png

"Because of advancements in testing and treatment options, patients like me are thriving. RichardsStory.com is about everyone who benefits from the life-saving possibilities offered by personalized medicine. This is a place for patients and their families to share their stories." 

-Richard Heimler, Non-Small Cell Lung Cancer Patient

 

 


 


Meet Richard Heimler

Richard Heimler was only 44 when he was diagnosed with Non-Small Cell Lung Cancer (NSCLC). And as treatment after treatment failed, the diagnosis felt like a death sentence... until his physician had Richard tested with the Vysis ALK test. Richard's Vysis ALK status confirmed that he qualified for a new clinical trial studying a highly targeted biomarker-based drug therapy (later approved by the FDA in August 2011). Suddenly, Richard gained a new lease on life. Watch the video to see his amazing story. 

 

In honor of the 10th anniversary of his initial lung cancer diagnosis, survivor Richard Heimler turned the negative into a positive perspective on life. This story highlights Richard's inspiration for producing the documentary Richard's Rays of Hope

Click to view Richard's Rays of Hope, a documentary that chronicles  Richard Heimler’s efforts to spread hope and bring awareness to lung cancer.  


 

 

Meet Linda Carey

Identified as HER2 positive, breast cancer patient, Linda Carey, entered the HERCEPTIN® clinical trial. About 18 months after she stopped Herceptin, her doctors found cancer in her liver. Since then, she has been receiving treatment and is happy to say her cancer is stable. As a way of dealing with the diagnosis, Linda’s husband, Bob, began taking photographs of himself in a pink tutu. The pictures are fun and tell a story about cancer in a memorable way. Linda and Bob launched the Carey Foundation to help raise funds to cover the incidental costs of cancer. Click here for more about Linda’s story.    


 

 

Meet Donna Gaidamak

In 2007, frequent stomach and headaches triggered Donna Gaidamak’s primary care physician to send her for a CT scan and MRI. Three small lesions were found on her brain and a biopsy revealed she had Stage 4 lung cancer that had metastasized to her brain. Donna was tested for the ALK gene rearrangement with the Vysis ALK FISH test from Abbott.  Results proved she was ALK positive and she was immediately put on XALKORI®. Today, Donna is back to doing the activities she loves -biking, skiing, kayaking and sailing.  Click here to learn about Donna’s journey.

 

 


 

Meet Roseann Kolb 

Roseann Kolb was 50 years old when she discovered through a mammogram that she had advanced stage breast cancer. Physicians performed a biopsy and additional tests, including Abbott’s PathVysion test, which determined that Roseann was HER-2 positive. Her medical team recommended a mastectomy, chemotherapy, radiation and HERCEPTIN® treatment, and, years later, reconstructive surgery. Her doctors tell her that her success story represents how a patient’s odds improve when diagnosis and treatment are optimized. Click on Roseann’s video to learn how successful treatment has allowed her to enjoy retirement with her husband and family.    


 

 

Meet Matt Ellefson

In December of 2009, Matt Ellefson was diagnosed with late stage Non-Small Cell Lung Cancer. He was told that without treatment, he would have eight months to live. After an extensive search, Matt entered a clinical trial and underwent five months of aggressive treatments. In August 2011, his cancer returned. While waiting at his oncologist’s office, Matt researched the latest treatment options on his smart phone. He read about crizotinib (XALKORI®) and asked his physician if ALK gene rearrangement testing was right for him. The Vysis ALK FISH Test showed Matt had the ALK gene rearrangement and his physician started him on XALKORI® immediately. He’s since run his first half-marathon. Click here to see Matt’s inspiring story. 


Vysis ALK Break Apart FISH Probe Kit
Intended Use: The Vysis ALK Break Apart FISH Probe Kit is a test to detect rearrangements involving the ALK gene in tissue samples from non-small cell lung cancer (NSCLC) patients to aid in identifying those patients eligible for treatment with XALKORI® (crizotinib). 

Limitations: The clinical interpretation of any test results should be evaluated within the context of the patient's medical history and other diagnostic laboratory test results. 
Rx only
For In Vitro Diagnostic Use

PathVysion HER-2 DNA Probe Kit
Intended Use:
 The Vysis PathVysion HER-2 DNA Probe Kit is a test to detect amplification of the HER-2/neu gene in tissue samples from breast cancer patients to aid in determining and identifying those patients eligible for treatment with HERCEPTIN®. 
Limitations: The clinical interpretation of any test results should be evaluated within the context of the patient's medical history and other diagnostic laboratory test results. 
Rx only
For In Vitro Diagnostic Use